FIELD: medicine.
SUBSTANCE: invention relates to medicine, namely to oncology, and can be used in the treatment of skin melanoma of stages IIb-IIc. The method includes courses of chemotherapy with dacarbazine immediately after surgery, three times for 5 days by intravenous administration at doses of 250 mg/m2 of the patient’s body area with an interval between courses of 3-4 weeks. After chemotherapy, interferon-α 3-5 million units immunotherapy is performed 3 times a week for a total duration of 12 months.
EFFECT: use of the invention makes it possible for patients with stage IIb- IIc skin melanoma to gain an advantage in progression-free survival, as well as in adjusted overall survival.
1 cl, 2 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF TREATING STAGE 0-IIC EXTREMITY SKIN MELANOMA | 2024 |
|
RU2828955C1 |
| METHOD FOR PREDICTING THE EFFECTIVENESS OF ADJUVANT INTERFERON THERAPY OF SKIN MELANOMA | 2019 |
|
RU2722403C1 |
| METHOD FOR DETERMINING THE DEGREE OF AGGRESSIVENESS OF THE COURSE OF SKIN MELANOMA | 2021 |
|
RU2754100C1 |
| METHOD FOR BIOPSY OF SENTINEL LYMPH NODES IN SURGICAL TREATMENT OF LOCAL MELANOMA OF TRUNK AND EXTREMITIES SKIN | 2023 |
|
RU2818094C1 |
| METHOD FOR APPLYING COMBINED SKIN MELANOMA TREATMENT | 2006 |
|
RU2312687C1 |
| METHOD OF TREATING UVEAL MELANOMA | 2000 |
|
RU2175242C1 |
| METHOD OF TREATING ONCOLOGICAL PATIENTS WITH CYTOTOXIC LYMPHOCYTES | 2015 |
|
RU2596505C1 |
| SET OF DRUGS FOR CONDUCTING A COURSE OF TERTIARY PREVENTION OF ONCOLOGICAL DISEASES FOR IMMUNOMODULATORY EFFECTS IN COMBINATION THERAPY AND A METHOD FOR TERTIARY PREVENTION OF ONCOLOGICAL DISEASES USING COMBINATION THERAPY USING A SET OF DRUGS FOR IMMUNOMODULATING EFFECTS | 2022 |
|
RU2794024C1 |
| METHOD FOR PREDICTING METASTASES IN PATIENTS WITH SKIN MELANOMA | 2014 |
|
RU2546035C1 |
| METHOD FOR TREATING SKIN MELANOMA OF BODY OR LIMBS | 2005 |
|
RU2295920C1 |
